Candel Therapeutics, Inc. financial data

Symbol
CADL on Nasdaq
Location
Needham, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 469% % 155%
Debt-to-equity 29% %
Return On Equity -29% % -101%
Return On Assets -23% % 87%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54,898,303 shares 69%
Common Stock, Shares, Outstanding 54,895,849 shares 71%
Entity Public Float $162,900,000 USD 478%
Common Stock, Value, Issued $550,000 USD 71%
Weighted Average Number of Shares Outstanding, Basic 54,894,347 shares 71%
Weighted Average Number of Shares Outstanding, Diluted 54,894,347 shares 71%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $24,285,000 USD 12%
General and Administrative Expense $16,370,000 USD 19%
Operating Income (Loss) $40,655,000 USD -14%
Nonoperating Income (Expense) $17,896,000 USD
Net Income (Loss) Attributable to Parent $22,759,000 USD 56%
Earnings Per Share, Basic 0 USD/shares 69%
Earnings Per Share, Diluted 0 USD/shares 68%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $86,963,000 USD 425%
Assets, Current $90,134,000 USD 398%
Property, Plant and Equipment, Net $1,363,000 USD -45%
Operating Lease, Right-of-Use Asset $1,750,000 USD 185%
Assets $93,598,000 USD 335%
Accounts Payable, Current $1,118,000 USD 278%
Employee-related Liabilities, Current $2,570,000 USD 9.9%
Accrued Liabilities, Current $5,149,000 USD 13%
Liabilities, Current $10,929,000 USD -28%
Operating Lease, Liability, Noncurrent $1,572,000 USD 183%
Liabilities $13,474,000 USD -63%
Retained Earnings (Accumulated Deficit) $200,891,000 USD -13%
Stockholders' Equity Attributable to Parent $80,124,000 USD
Liabilities and Equity $93,598,000 USD 335%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,616,000 USD -2.1%
Net Cash Provided by (Used in) Financing Activities $1,870,000 USD -49%
Net Cash Provided by (Used in) Investing Activities $3,000 USD 57%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 55,018,457 shares 71%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $10,489,000 USD -8.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $87,229,000 USD 418%
Interest Paid, Excluding Capitalized Interest, Operating Activities $252,000 USD -54%
Deferred Tax Assets, Valuation Allowance $52,185,000 USD 29%
Deferred Tax Assets, Gross $52,462,000 USD 28%
Operating Lease, Liability $2,009,000 USD 81%
Depreciation $984,000 USD 0.31%
Payments to Acquire Property, Plant, and Equipment $3,000 USD -57%
Lessee, Operating Lease, Liability, to be Paid $2,441,000 USD 107%
Property, Plant and Equipment, Gross $4,790,000 USD -9.8%
Operating Lease, Liability, Current $437,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Two $613,000 USD 48%
Lessee, Operating Lease, Liability, to be Paid, Year One $618,000 USD 0.82%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $432,000 USD 492%
Lessee, Operating Lease, Liability, to be Paid, Year Three $628,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $29,876,000 USD 29%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $426,000 USD
Operating Lease, Payments $802,000 USD 37%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $277,000 USD -45%
Share-based Payment Arrangement, Expense $3,771,000 USD -25%
Interest Expense $3,087,000 USD -9.6%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%